Ignite Creation Date:
2024-05-05 @ 4:41 PM
Last Modification Date:
2024-10-26 @ 9:23 AM
Study NCT ID:
NCT00291642
Status:
COMPLETED
Last Update Posted:
2018-09-11
First Post:
2006-02-10
Brief Title:
A Study to Compare the Efficacy of Levocetirizine to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis SAR in Sensitive Subjects Exposed to Ragweed Pollen
Sponsor:
UCB Pharma
Organization:
UCB Pharma
Study Overview
Official Title:
Double Blind Double-dummy Five Parallel Groups Randomized Exploratory Clinical Trial to Compare the Efficacy of Single Dose of Levocetirizine 25 mg Oral Drops 5 mgmL Levocetirizine 5 mg Oral Tablets Cetirizine 5 mg Oral Drops 10 mgmL and Cetirizine 10 mg Oral Tablets to Placebo in Reducing Symptoms of Seasonal Allergic Rhinitis SAR in Ragweed Sensitive Subjects Exposed to Ragweed Pollen in an Environmental Exposure Unit EEU
Status:
COMPLETED
Status Verified Date:
2018-08-01
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of the study is to assess the efficacy comparability of cetirizine and levocetirizine by comparing the effects of single intake of the two drugs to placebo in reducing symptoms of seasonal allergic rhinitis SAR in ragweed sensitive adult subjects exposed to ragweed pollen in an Environmental Exposure Unit
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None